trial

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

NCTId NCT04659174
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 152 (actual)
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Primary completion 2023-10-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
152 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2021-02-01
Primary completion
2023-10-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Karuna Therapeutics, Inc., a Bristol Myers Squibb companyLead Sponsor

Sites

44 total
Bentonville, United StatesLittle Rock, United StatesAnaheim, United StatesBellflower, United StatesBellflower, United StatesCulver City, United StatesGarden Grove, United StatesGlendale, United StatesLemon Grove, United StatesLong Beach, United StatesMontclair, United StatesOrange, United States

Linked catalysts

1
An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of Kar — primary completion2023-10-03

Facts & assertions

4 sourced
Enrollment
152
Phase
PHASE3
Primary Completion Date
2023-10-03
Status
COMPLETED
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
company
indication
Schizophrenia
indication
Schizophrenia
indication